Please revisit my last post as I clearly made the
Post# of 72440
Phase 3 trials are expensive. IMO north of $20M. You may not think so. That is your opinion.
IPIX will need to finance either with their shelf OR through a partnership.
Not contradictory.
Not coincidentally, IPIX is looking for a partner. Why? To progress a drug to market (phase 3, NDA), in which case they should not need to drain the shelf.
Gimmee a break. Can this not be clearer?
Not everyone is out to "attack" the stock you own by posting on IHub.